These are broader spectrum bactericidal anti-MRSA drugs derived from (a novel sub-class of quinolone) benzoquinolizine fluoroquinolone levonadifloxacin. The novel structural attributes of levonadifloxacin leads to a differentiated mechanism of action against MRSA. Unlike classical quinolones essentially targeting bacterial Topoisomerase IV, levonadifloxacin preferentially targets key bacterial enzyme DNA Gyrase along with Topoisomerase IV leading to high potency even against levofloxacin and moxifloxacin resistant staphylococci and MRSA. Moreover, levonadifloxacin inhibits a staphylococcal efflux pump Nor A implicated for wide spread resistance to quinolones such as ciprofloxacin, norfloxacin, clinafloxacin and gemifloxacin. Thus, WCK 771/2349 overcomes three known mechanisms of resistance to quinolones in MRSA viz, Nor A, mutations in Topo IV and DNA Gyrase. WCK 771 is also active against MRSA biofilms, a feature desirable for improved outcome in pneumonia and bone and joint infections.
WCK 2349 is an oral aminoacid ester prodrug of levonadifloxacin with remarkably high oral bioavailability.
WCK 771/2349 : Resistant Pathogen coverage:
- MRSA , MRSE, Methicillin sensitive Staphylococci, CA-MRSA ( Community MRSA)
- VRSA ( vancomycin resistant Staph) , VISA ( vancomycin intermediate Staph)
- MDR Pneumococci
- Erythromycin resistant-Group A Streptococci
- Clindamycin resistant-Group B Streptococci
- E.coli, Klebsiella, Enterobacter, Salmonella
- Gram Positive & GramNegative anaerobes
WCK 771/2349 : Indication Potential
- Acute bacterial skin and skin structure infections
- Hospital acquired pneumonia caused by MRSA
- Diabetic foot infections
- Community acquired pneumonia